1. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine- Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation 
Martino Introna, Federico Lussana, Alessandra Algarotti, Elisa Gotti, Rut Valgardsdottir, Caterina Micò, Anna Grassi, Chiara Pavoni, Maria Luisa Ferrari, Federica Delaini, Elisabetta Todisco, Irene Cavattoni, Sara Deola, Ettore Biagi, Adriana Balduzzi, Attilio Rovelli, Matteo Parma, Sara Napolitano, Giusy Sgroi, Emanuela Marrocco, Paolo Perseghin, Daniela Belotti, Benedetta Cabiati, Giuseppe Gaipa, Josée Golay, Andrea Biondi, Alessandro Rambaldi 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 12, Pages (December 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Treatment scheme and dosages. (Top) Scheme of DLI and CIK cell infusions is summarized. (Bottom) Escalating doses of CIK cells, corresponding to the 4 triplets of patients of the “safety trial,” are shown.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Treatment flow. The number of patients enrolled, allocated to CIK cell treatment, and who completed the 2 DLI and 3 CIK cell infusions are shown schematically. Patients who could not complete the therapeutic program are indicated on the right, with the main reasons for not receiving the cells.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3 Cumulative incidence of GVHD. (A) aGVHD; (B) cGVHD.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4 Clinical outcomes of patients. (A) PFS; (B) OS.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Clinical outcomes according to type of relapse. The outcome of patients with either hematologic (dashed line) or cytogenetic and molecular relapse (continuous line) are shown. (A) PFS; (B) OS.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

7. Figure 6
Clinical outcomes in AML and ALL patients according to type of relapse.
The outcome of patients with either hematologic (dashed line) or cytogenetic and molecular relapse (continuous line) are shown. (A) AML; (B) ALL.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions